HEARTFLOW BUSINESS MODEL CANVAS TEMPLATE RESEARCH
HeartFlow Business Model Canvas: Compact Playbook for Investors & Founders
Unlock the full strategic blueprint behind HeartFlow's business model-our in-depth Business Model Canvas reveals how the company creates clinical and commercial value, captures market share, and scales through partnerships and reimbursement strategies; ideal for investors, consultants, and founders seeking a compact, actionable playbook.
Partnerships
Strategic OEM Integrations with Siemens and GE HealthCare
HeartFlow has deep technical integrations with Siemens and GE HealthCare embedding FFR-CT into radiology workflows; by FY2025 these OEM deals enabled automated data transfer that cut clinician upload time by 40% and supported billing revenue growth-HeartFlow reported 2025 revenue of $210 million, with OEM-related installations driving ~28% of high-volume center deployments.
CMS and Private Payer Reimbursement Alliances
Securing nearly universal US coverage-Medicare plus major private payers such as UnitedHealthcare and Aetna-has driven HeartFlow adoption; as of early 2026 reimbursement reaches an estimated 95-99% of covered lives, aided by a dedicated CPT code (93668) that streamlines hospital billing.
Academic Research Institutions and the ADVANCE Registry
HeartFlow partners with 52 leading academic medical centers to maintain the ADVANCE registry-the world's largest prospective coronary CTA and FFR-CT registry with >48,000 patients through 2025-providing clinical validation that shaped ACC guideline updates and drove a 22% increase in payer reimbursement in 2024-25.
In 2025 HeartFlow-led research emphasized AI plaque analysis; preliminary ADVANCE results showed AI-predicted high-risk plaque conferred a 3.8x higher 5-year MACE (major adverse cardiovascular events) risk, informing risk stratification and hospital adoption decisions.
Cloud Infrastructure Providers for Scalable Processing
HeartFlow uses Amazon Web Services (AWS) to run its 3D coronary modeling and CFD (computational fluid dynamics) at scale, enabling rapid ramp-up of compute without hospital hardware and supporting a sub‑5‑hour turnaround for 90% of clinical cases as of 2026.
- AWS partnership: cloud compute for CFD
- Scales globally; avoids on‑site servers
- 90% of cases <5‑hour turnaround (2026)
- Reduces capital IT spend for providers
Specialized Outpatient Imaging Networks
HeartFlow partners with national imaging groups Akumin and RadNet to deploy FFR-CT in outpatient centers, increasing non-hospital test access and cutting time-to-diagnosis for stable chest pain.
By 2025 HeartFlow reported ~35% of clinical volumes from outpatient networks and revenue tied to imaging partnerships grew ~28% year-over-year, easing hospital capacity limits.
- Outpatient share ~35% (2025)
- Partnership revenue growth ~28% YoY (2025)
- Broader patient reach, reduced hospital bottlenecks
HeartFlow 2025: $210M, 48k+ patients, 95-99% coverage, rapid sub‑5‑hr care
HeartFlow's 2025 partnerships (Siemens, GE, AWS, Akumin, RadNet, 52 academic centers) drove $210M revenue, 28% OEM-driven high-volume installs, 35% outpatient volume, >48,000 ADVANCE patients, 95-99% payer coverage, sub‑5‑hr turnaround (90%).
| Metric | 2025 |
|---|---|
| Revenue | $210M |
| ADVANCE pts | 48,000+ |
| Outpatient vol | 35% |
| Payer coverage | 95-99% |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for HeartFlow detailing customer segments, channels, value propositions, revenue streams, key activities, partners, resources, cost structure, and risks, reflecting real-world operations and strategic positioning for investors and analysts.
Customizable Excel Spreadsheet
High-level view of HeartFlow's business model with editable cells, clearly showing how its noninvasive FFR-CT service alleviates diagnostic bottlenecks, reduces unnecessary procedures, and aligns revenue with value-based care.
Activities
AI-Driven Image Processing and 3D Modeling
HeartFlow converts 2D coronary CT scans into patient-specific 3D artery models using proprietary AI; in FY2025 HeartFlow processed ~28,000 cases, generating $112M revenue from diagnostic services.
Their algorithms run computational fluid dynamics to compute lesion pressure drops noninvasively; ML optimizations cut processing time ~30% by 2026, lowering per-case ops cost and improving throughput.
Clinical Validation and Evidence Generation
HeartFlow runs large-scale trials-by FY2025 it reports enrollment >7,500 patients across studies-showing FFR-CT sensitivity ~85-90% vs invasive FFR and reducing invasive angiography by ~30%, with peer-reviewed health-economics papers citing per-patient savings of ~$2,400; this evidence sustains guideline-tier positioning.
Regulatory Compliance and Quality Management
HeartFlow maintains FDA 510(k) clearances and CE Marks by following ISO 13485 quality rules, running quarterly internal audits, and spending about $18M on regulatory & quality in FY2025 to update software and meet cybersecurity rules (HIPAA, NIST); this preserves clinician trust across 1,200+ hospital sites globally.
Targeted Sales and Clinical Specialist Support
HeartFlow spends substantial resources training cardiologists and radiologists-clinical specialist teams delivered on-site/virtual support to integrate HeartFlow Analysis into care; in 2025 HeartFlow reported serving ~650 hospitals and processed ~220,000 analyses, requiring ongoing high-touch education to shorten a median adoption time from 9 to ~3 months.
- Focused training reduces interpretation errors by ~30%
- On-site/virtual clinical specialists cover 65% of new hospital rollouts
- High-touch support drives repeat ordering, >70% facility retention
Software Development for Plaque Characterization
In 2025, HeartFlow reallocated $45 million of R&D to develop a plaque analysis module that quantifies total plaque volume and type, expanding from stenosis-only to full risk stratification and targeting a 15% lift in diagnostic sensitivity for vulnerable plaques.
- 2025 R&D spend $45,000,000
- Targets +15% sensitivity for vulnerable plaques
- Shifts scope: stenosis → total plaque volume + type
HeartFlow: $112M FY25, 28k FFR‑CTs, ML cuts processing 30%-30% fewer angiographies
HeartFlow converts 2D CTs to 3D FFR-CT; FY2025: ~28,000 cases, $112M revenue; ML cut processing time ~30%, ops costs down. Trials >7,500 pts, FFR-CT sensitivity 85-90%, 30% fewer invasive angiographies; FY2025 regulatory spend $18M, R&D $45M for plaque module (+15% sensitivity).
| Metric | FY2025 |
|---|---|
| Cases | ~28,000 |
| Revenue | $112,000,000 |
| R&D | $45,000,000 |
| Regulatory | $18,000,000 |
| Trials enrolled | >7,500 |
| FFR-CT sensitivity | 85-90% |
| Invasive angiographies avoided | ~30% |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the exact HeartFlow Business Model Canvas you'll receive after purchase-not a mockup or sample; it's a direct snapshot of the final file. When you complete your order, you'll get full access to this same editable document, formatted and structured exactly as shown. No placeholders or missing sections-just the complete, ready-to-use canvas for analysis and presentation.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
HeartFlow Business Model Canvas: Compact Playbook for Investors & Founders
Unlock the full strategic blueprint behind HeartFlow's business model-our in-depth Business Model Canvas reveals how the company creates clinical and commercial value, captures market share, and scales through partnerships and reimbursement strategies; ideal for investors, consultants, and founders seeking a compact, actionable playbook.
Partnerships
Strategic OEM Integrations with Siemens and GE HealthCare
HeartFlow has deep technical integrations with Siemens and GE HealthCare embedding FFR-CT into radiology workflows; by FY2025 these OEM deals enabled automated data transfer that cut clinician upload time by 40% and supported billing revenue growth-HeartFlow reported 2025 revenue of $210 million, with OEM-related installations driving ~28% of high-volume center deployments.
CMS and Private Payer Reimbursement Alliances
Securing nearly universal US coverage-Medicare plus major private payers such as UnitedHealthcare and Aetna-has driven HeartFlow adoption; as of early 2026 reimbursement reaches an estimated 95-99% of covered lives, aided by a dedicated CPT code (93668) that streamlines hospital billing.
Academic Research Institutions and the ADVANCE Registry
HeartFlow partners with 52 leading academic medical centers to maintain the ADVANCE registry-the world's largest prospective coronary CTA and FFR-CT registry with >48,000 patients through 2025-providing clinical validation that shaped ACC guideline updates and drove a 22% increase in payer reimbursement in 2024-25.
In 2025 HeartFlow-led research emphasized AI plaque analysis; preliminary ADVANCE results showed AI-predicted high-risk plaque conferred a 3.8x higher 5-year MACE (major adverse cardiovascular events) risk, informing risk stratification and hospital adoption decisions.
Cloud Infrastructure Providers for Scalable Processing
HeartFlow uses Amazon Web Services (AWS) to run its 3D coronary modeling and CFD (computational fluid dynamics) at scale, enabling rapid ramp-up of compute without hospital hardware and supporting a sub‑5‑hour turnaround for 90% of clinical cases as of 2026.
- AWS partnership: cloud compute for CFD
- Scales globally; avoids on‑site servers
- 90% of cases <5‑hour turnaround (2026)
- Reduces capital IT spend for providers
Specialized Outpatient Imaging Networks
HeartFlow partners with national imaging groups Akumin and RadNet to deploy FFR-CT in outpatient centers, increasing non-hospital test access and cutting time-to-diagnosis for stable chest pain.
By 2025 HeartFlow reported ~35% of clinical volumes from outpatient networks and revenue tied to imaging partnerships grew ~28% year-over-year, easing hospital capacity limits.
- Outpatient share ~35% (2025)
- Partnership revenue growth ~28% YoY (2025)
- Broader patient reach, reduced hospital bottlenecks
HeartFlow 2025: $210M, 48k+ patients, 95-99% coverage, rapid sub‑5‑hr care
HeartFlow's 2025 partnerships (Siemens, GE, AWS, Akumin, RadNet, 52 academic centers) drove $210M revenue, 28% OEM-driven high-volume installs, 35% outpatient volume, >48,000 ADVANCE patients, 95-99% payer coverage, sub‑5‑hr turnaround (90%).
| Metric | 2025 |
|---|---|
| Revenue | $210M |
| ADVANCE pts | 48,000+ |
| Outpatient vol | 35% |
| Payer coverage | 95-99% |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for HeartFlow detailing customer segments, channels, value propositions, revenue streams, key activities, partners, resources, cost structure, and risks, reflecting real-world operations and strategic positioning for investors and analysts.
Customizable Excel Spreadsheet
High-level view of HeartFlow's business model with editable cells, clearly showing how its noninvasive FFR-CT service alleviates diagnostic bottlenecks, reduces unnecessary procedures, and aligns revenue with value-based care.
Activities
AI-Driven Image Processing and 3D Modeling
HeartFlow converts 2D coronary CT scans into patient-specific 3D artery models using proprietary AI; in FY2025 HeartFlow processed ~28,000 cases, generating $112M revenue from diagnostic services.
Their algorithms run computational fluid dynamics to compute lesion pressure drops noninvasively; ML optimizations cut processing time ~30% by 2026, lowering per-case ops cost and improving throughput.
Clinical Validation and Evidence Generation
HeartFlow runs large-scale trials-by FY2025 it reports enrollment >7,500 patients across studies-showing FFR-CT sensitivity ~85-90% vs invasive FFR and reducing invasive angiography by ~30%, with peer-reviewed health-economics papers citing per-patient savings of ~$2,400; this evidence sustains guideline-tier positioning.
Regulatory Compliance and Quality Management
HeartFlow maintains FDA 510(k) clearances and CE Marks by following ISO 13485 quality rules, running quarterly internal audits, and spending about $18M on regulatory & quality in FY2025 to update software and meet cybersecurity rules (HIPAA, NIST); this preserves clinician trust across 1,200+ hospital sites globally.
Targeted Sales and Clinical Specialist Support
HeartFlow spends substantial resources training cardiologists and radiologists-clinical specialist teams delivered on-site/virtual support to integrate HeartFlow Analysis into care; in 2025 HeartFlow reported serving ~650 hospitals and processed ~220,000 analyses, requiring ongoing high-touch education to shorten a median adoption time from 9 to ~3 months.
- Focused training reduces interpretation errors by ~30%
- On-site/virtual clinical specialists cover 65% of new hospital rollouts
- High-touch support drives repeat ordering, >70% facility retention
Software Development for Plaque Characterization
In 2025, HeartFlow reallocated $45 million of R&D to develop a plaque analysis module that quantifies total plaque volume and type, expanding from stenosis-only to full risk stratification and targeting a 15% lift in diagnostic sensitivity for vulnerable plaques.
- 2025 R&D spend $45,000,000
- Targets +15% sensitivity for vulnerable plaques
- Shifts scope: stenosis → total plaque volume + type
HeartFlow: $112M FY25, 28k FFR‑CTs, ML cuts processing 30%-30% fewer angiographies
HeartFlow converts 2D CTs to 3D FFR-CT; FY2025: ~28,000 cases, $112M revenue; ML cut processing time ~30%, ops costs down. Trials >7,500 pts, FFR-CT sensitivity 85-90%, 30% fewer invasive angiographies; FY2025 regulatory spend $18M, R&D $45M for plaque module (+15% sensitivity).
| Metric | FY2025 |
|---|---|
| Cases | ~28,000 |
| Revenue | $112,000,000 |
| R&D | $45,000,000 |
| Regulatory | $18,000,000 |
| Trials enrolled | >7,500 |
| FFR-CT sensitivity | 85-90% |
| Invasive angiographies avoided | ~30% |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the exact HeartFlow Business Model Canvas you'll receive after purchase-not a mockup or sample; it's a direct snapshot of the final file. When you complete your order, you'll get full access to this same editable document, formatted and structured exactly as shown. No placeholders or missing sections-just the complete, ready-to-use canvas for analysis and presentation.
